Dhingra Kapil is a director of Black Diamond Therapeutics Inc.
Person profile
Roles
Address
Tenafly, New Jersey
Employees
SEC CIK
Latest filings (excl ownership)
No filings
Latest ownership filings
4
CARGO Therapeutics, Inc.
17 Apr 24
3
CARGO Therapeutics, Inc.
17 Apr 24
4
Replimune Group, Inc.
3 Apr 24
4
Black Diamond Therapeutics, Inc.
17 May 23
4
Replimune Group, Inc.
4 Apr 23
4
Black Diamond Therapeutics, Inc.
13 Jun 22
4
Replimune Group, Inc.
5 Apr 22
4
Black Diamond Therapeutics, Inc.
22 Jun 21
4
FIVE PRIME THERAPEUTICS, INC.
19 Apr 21
4
Replimune Group, Inc.
5 Apr 21
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | CRGX CARGO Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 19.89 | 49,265 | 979.88 k | 49,265 |
1 Apr 24 | REPL Replimune | Stock Option Common Stock | Grant | Acquire A | No | No | 7.73 | 32,000 | 247.36 k | 32,000 |
16 May 23 | BDTX Black Diamond Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 1.82 | 16,500 | 30.03 k | 16,500 |
1 Apr 23 | REPL Replimune | Stock Option Common Stock | Grant | Acquire A | No | No | 17.66 | 25,200 | 445.03 k | 25,200 |